AbbVie claimed FDA approval for its JAK inhibitor Rinvoq (upadacitinib) for rheumatoid arthritis on Friday, setting its price just a little below that of its antibody blockbuster Humira.
(American Journal of Gastroenterology) Real-world data confirmed the effectiveness of upadacitinib (Rinvoq) in Crohn's disease, with clinical remission achieved in 56% of patients at 6 months ...